Marketing analysis of the Russian pharmaceutical market for treatment of neovascular age-related macular degeneration

Background. Studies on the pharmaceutical provision of neovascular age-related macular degeneration with angiogenesis inhibitors in the Russian Federation have repeatedly indicated a mismatch between the level of consumption and the actual need for these drugs. This highlights the importance of further research on the issue through marketing analysis.

Objective: To conduct a marketing analysis of the market for angiogenesis inhibitors used in the treatment of neovascular age-related macular degeneration, including assessment of the product range, price dynamics, demand and consumption, as well as index analysis for the period of 2018–2024.

Material and methods. The study was based on open data on the procurement of angiogenesis inhibitors in the public sector, price characteristics, and information on consumption with compulsory health insurance system (24-hour and day hospitals as well as high-tech medical care). The scientific and methodological framework of the study included methods for analyzing the sales of drugs from the group of angiogenesis inhibitors registered for medical use in the Russian Federation, as well as methodological tools for calculating a series of chain indices (including the weighted average price index, price index, structural shift index, index of changes in sales volumes in physical terms, modified Herfindahl–Hirschman index). Methods for analyzing the life cycle of the drugs and comparing the volumes of their procurement and consumption volumes were also used.

Results. During the study period, there was a noticeable increase in the demand for and consumption of angiogenesis inhibitors: procurement volumes in physical terms grew 2.53-fold, and in monetary terms 1.62-fold. The positive dynamics of the market for the studied group of drugs were accompanied by an increase in weighted average prices and a growing share of more expensive drugs in the procurement structure. Between 2021 and 2023, uneven growth was observed in procurement volumes in physical terms and in the number of hospitalizations involving the use of these drugs. The ratio of hospitalization volumes to procurement volumes during this period was 1.21, 1.46, and 1.47, respectively, indicating that a single vial of the drug was used for multiple patients. The disproportion between procurement volumes and the number of hospitalizations points to a significant additional potential demand for angiogenesis inhibitors. The current market conditions can be characterized as attractive for manufacturers and suppliers.

Conclusion. It was established that the market for angiogenesis inhibitors was characterized by both qualitative and quantitative growth, with sustained positive development dynamics. The identified features of procurement and consumption indicate the need for further research aimed at developing optimal solutions for ensuring the pharmaceutical provision of angiogenesis inhibitors to consumers in the required range and sufficient volumes.

1. Clinical guidelines “Age-related macular degeneration”. Association of Ophthalmologists. 2024. Available at: http://avo-portal.ru/doc1/%D0%9A%D0%A0%20114.pdf (accessed 25.02.2025).

2. Neroev V.V., Zaytseva O.V., Petrakovskaya V.A., et al. The first Russian register of patients with neovascular age-related macular degeneration: a real-world clinical study. Russian Ophthalmological Journal. 2023; 16 (4): 7–26 (in Russ.). https://doi.org/10.21516/2072-0076-2023-164-supplement-7-26.

3. Vlasov Ya.V., Fomina Т.А., Sineok E.V., Svetozarskiy S.N. Assessment of medical care accessibility for retinal diseases in the regions of the Russian Federation: opinions of doctors and patients. Saratov Journal of Medical Scientific Research. 2024; 20 (2): 198–202 (in Russ.). https://doi.org/10.15275/ssmj2002198.

4. Laricheva I.V., Son I.M., Yastrebova E.S., et al. The evaluation of epidemiology and the availability of medical care for patients with retina diseases in the Russian Federation. Manager zdravoohranenia. 2020; 10: 26–36 (in Russ.). https://doi.org/10.37690/1811-0185-2020-10-26-36.

5. Kovaleva S.A., Fedyaev D.V., Seryapina Yu.V. Actual issues of providing and paying for medical care within compulsory medical insurance in patients with retinal diseases. Medical Technologies. Assessment and Choice. 2021; 43 (1): 63–72 (in Russ.). https://doi.org/10.17116/medtech20214301163.

6. Ivakhnenko O.I., Neroev V.V., Zaytseva O.V. Age-related macular degeneration and diabetic eye lesion. Socio-economic aspects. Russian Annals of Ophthalmology. 2021; 137 (1): 123–9 (in Russ.). https://doi.org/10.17116/oftalma2021137011123.

7. Trofimova E.O., Denisova M.N., Orlov A.S. Development of the Russian pharmaceutical market: index analysis. Farmatsiya. 2019; 68 (6): 5–10 (in Russ.).

8. Trofimova E.O. Marketing in pharmacy: methodology of pharmaceutical market research. Мoscow: Yurayt; 2024: 114 pp. (in Russ.).

9. Gorkavenko F.V. Frequency analysis of intravitreal therapy in patients with degeneration of macular and posterior pole in the Russian Federation from 2021 to 2023. In: EurasiaScience: collection of articles from the LXI International Scientific and Practical Conference. Мoscow: Aktualnost.RF LLC; 2024: 37–39 (in Russ.).

10. Bobykin E.V., Morozova O.V., Krokhalev V.Ya., Varezhkina E.S. Intraocular inflammation associated with intravitreal drug injections: current state of the problem. Ophthalmology Eastern Europe. 2024; 14 (1): 129–45 (in Russ.). https://doi.org/10.34883/PI.2024.14.1.025.

11. Bobykin E.V., Morozova O.V., Buslaev R.V. Duration of anti-VEGF therapy of neovascular macular diseases in real clinical practice. Practical Medicine. 2017; 2 (9): 43–8 (in Russ.).

12. Bavinger J.C., Yu Y., VanderBeek B.L. Comparative risk of endophthalmitis after intravitreal injection with bevacizumab, aflibercept, and ranibizumab. Retina. 2019; 39 (10): 2004–11. https://doi.org/10.1097/IAE.0000000000002351.

13. Blom K., Bragadóttir R., Sivertsen M.S., et al. Does pharmaceutical compounding of vascular endothelial growth factor inhibitors for intravitreal use alter the risk of post-injection endophthalmitis? Ocul Immunol Inflamm. 2022; 30 (3): 713–6. https://doi.org/10.1080/09273948.2020.1820530.

14. Goldberg R.A., Flynn H.W. Jr., Miller D., et al. Streptococcus endophthalmitis outbreak after intravitreal injection of bevacizumab: one-year outcomes and investigative results. Ophthalmology. 2013; 120 (7): 1448–53. https://doi.org/10.1016/j.ophtha.2012.12.009.

15. Khan P., Khan L., Mondal P. Cluster endophthalmitis following multiple intravitreal bevacizumab injections from a single use vial. Indian J Ophthalmol. 2016; 64 (9): 694–6. https://doi.org/10.4103/03014738.99855.

16. Chambers J.D., Beinfeld M.T., Richardson T., Pangrace M. Assessing variation in US payer coverage of anti-vascular endothelial growth factor therapies for the treatment of age-related macular degeneration, diabetic retinopathy, and diabetic macular edema. J Manag Care Spec Pharm. 2025; 31 (5): 451–60. https://doi.org/10.18553/jmcp.2025.2434.

17. Wang H., Bahrami B., Huang S., et al. Safety of an Intravitreal Bevacizumab Biosimilar (MVASI). Clin Exp Ophthalmol. 2025; Mar 5. https://doi.org/10.1111/ceo.14515.

18. Jain P., Sheth J., Anantharaman G., Gopalakrishnan M. Real-world evidence of safety profile of intravitreal bevacizumab (Avastin) in an Indian scenario. Ind J Ophthalmol. 2017; 65 (7): 596–602. https://doi.org/10.4103/ijo.IJO_992_16.

19. Lode H.E., Gjølberg T.T., Foss S., et al. A new method for pharmaceutical compounding and storage of anti-VEGF biologics for intravitreal use in silicone oil-free prefilled plastic syringes. Sci Rep. 2019; 9 (1): 18021. https://doi.org/10.1038/s41598-019-54226-7.

20. Lipatov D.V., Lyshkanets O.I. Intravitreal therapy of diabetic macular edema in Russian Federation: current state of the problem. Russian Annals of Ophthalmology. 2019; 135 (4): 128–39 (in Russ.). https://doi.org/10.17116/oftalma2019135041128.